Skip to main content
SpringerLink
Log in

Cellular transport of CI-980

  • Preclinical Studies
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

CI-980, originally synthesized as a potential folate antagonist, is a tubulin-binding mitotic inhibitor currently in pediatric phase I and adult phase II clinical trials. Because of its extensive tissue distribution in animals and its favorable activity against multidrug resistant (MDR) cells compared with other mitotic inhibitors, such as vincristine, we examined the membrane transport properties of CI-980. CI-980 accumulated rapidly in L1210 and CHO/K1 cells, reaching intracellular levels 40- and 8-fold higher, respectively, than those in the extracellular medium. Efflux was also quite rapid, but a small fraction of drug remained associated with the cells in drug-free medium. The uptake of CI-980 was not temperature or energy dependent, nor was it saturable up to an extracellular concentration of 100 μM. Inhibitors of nucleoside transport had no effect on CI-980 uptake. A cell line deficient in the transport of reduced folate was not resistant to CI-980, nor did it exhibit reduced CI-980 uptake. A 100-fold excess of the R-enantiomer inhibited CI-980 uptake by only 50%. These results are consistent with a model of CI-980 uptake involving passive diffusion followed by significant but largely reversible binding to intracellular or membrane components.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Temple C Jr, Wheeler GP, Elliott RD, Rose JD, Comber RN: 1,2-dihydropyrido[3,4-b]pyrazines: structure-activity relationships. J Med Chem 26:91–95, 1983

    Google Scholar 

  2. Bowdon BJ, Waud WR, Wheeler GP, Hain R, Dansby L, Temple C Jr: Comparison of 1,2-dihydropyrido[3,4-b]pyrazines (1-deaza-7,8-dihydropteridines) with several other inhibitors of mitosis. Cancer Res 47:1621–1626, 1987

    Google Scholar 

  3. Wheeler GP, Bowdon BJ, Temple C Jr, Adamson DJ, Webster J: Biological effects and structure-activity relationships of 1,2-dihydropyrido[3,4-b]pyrazines. Cancer Res 43:3567–3575, 1983

    Google Scholar 

  4. Griswold DP Jr, Temple CG Jr, Trader MW, Leopold WR III, Laster WR Jr, Dykes DJ: Antitumor activity of a novel 1,2 dihydropyrido[3,4-b]pyrazine in preclinical drug-sensitive and -resistent tumors. Proc Am Assoc Cancer Res 27:306, 1986

    Google Scholar 

  5. Waud WR, Leopold WR, Elliott WL, Dykes DJ, Laster WR Jr, Temple CG Jr, Harrison SD Jr, Griswold DP Jr: Antitumor activity of ethyl 5-amino-1,2-dihydro-2-methyl-3-phenylpyrido [3,4-b]pyrazin-7-ylcarbamate, 2-hydroxyethanesulfonate, hydrate (NSC 370147) against selected tumor systems in culture and in mice. Cancer Res 50:3239–3244, 1990

    Google Scholar 

  6. Leopold WR, Elliott WL, Przybranowski SA, Waud WR: In vivo evaluation of the potential for therapeutic synergy between CI-980 and standard chemotherapeutic agents. Proc Am Assoc Cancer Res 34:296, 1993

    Google Scholar 

  7. Noker PE, Hill DL, Kalin JR, Temple CG, Montgomery JA Jr: Pharmacokinetic and metabolism studies of two novel 1-deaza-7,8-dihydropteridines in mice. Drug Metabolism and Deposition 13:677, 1985

    Google Scholar 

  8. Sklarin NT, Benson L, Roca J, Einzig AI, Wiernik PH, Whitfield LR, Lathia C, Kowal C, Grove W: Phase I study of CI-980: 24-hr infusion schedule. Proc Am Soc Clin Oncol 14:479, 1995

    Google Scholar 

  9. Brodfuehrer J, Whitfield LR, Kowal C, Grove W, Bullen W, Waterhouse D, Natale R: Pharmacologically guided dose escalation in Phase I clinical trial of CI-980. Proc Am Assoc Cancer Res 33:529, 1992

    Google Scholar 

  10. Natale R, Waterhouse D, Grove W, Whitfield LR, Brodfuehrer J, Kowal C: Phase I clinical and pharmacokinetic trial of CI-980, a novel mitotic inhibitor. Proc Annu Meet Am Soc Clin Oncol 11:118, 1992

    Google Scholar 

  11. Rowinsky EK, Noe DA, Grochow LB, Bowling MK, Sartorious SE, O'Reilly S, Chen T-L, Donehower RC: Phase I and pharmacological study of CI-980, a synthetic and structurally unique antimicrotubule agent, on a 72-hour continuous infusion schedule in adults with solid tumors. Proc Am Soc Clin Oncol 14:459, 1995

    Google Scholar 

  12. Pazdur R, Diaz-Canton E, Meyers C, Abbruzzese J, Patt Y, Rivera E, Touroutoglou N, Edwards K, Bready B, Ajani JE: Phase II trial of CI-980 in metastatic colorectal carcinoma patients. Proc Am Assoc Clin Oncol 14:208, 1995

    Google Scholar 

  13. Verschraegen CF, Kudelka AP, Edwards CL, Meyers CA, Conrad CA, Freedman RS, Gonzalez de Leon C, Finnegan MB, Hord M, Mante R, Calayag M, Grove W: Phase II trial of CI-980 in advanced epithelial ovarian carcinoma. Proc Am Assoc Clin Oncol 14:271, 1995

    Google Scholar 

  14. Temple C Jr, Rener GA: Antimitotic agents: chiral isomers of ethyl 5-amino-1,2-dihydro-3-(4-hydroxyphenyl)-2-methylpyrido[3,4-b]pyrazin-7-ylcarbamate. J Med Chem 35: 988–993, 1992

    Google Scholar 

  15. Waud WR, Bowdon BJ, Temple CG Jr, Harrison SD Jr, Griswold DP Jr: Comparative antitumor activity and mechanistic studies of the S- and R-enantiomers of a novel 1,2-dihydropyrido-[3,4-b]pyrazine. Proc Am Assoc Cancer Res 30:565, 1989

    Google Scholar 

  16. De Ines C, Leynadier D, Barasoain I, Peyrot V, Garcia P, Briand C, Rener GA, Temple C Jr: Inhibition of microtubules and cell cycle arrest by a new 1-deaza-7,8-dihydropteridine antitumor drug, CI-980, and its chiral isomer, NSC 613863. Cancer Res 54:75–84, 1994

    Google Scholar 

  17. Fry DW, Besserer JA, Boritzki TJ: Transport of the antitumor antibiotic CI-980 into L1210 leukemia cells by the reduced Mate carrier system. Cancer Res 44:3366–3370, 1984

    Google Scholar 

  18. Fry DW, Besserer JA: Characterization of trimetrexate transport in human lymphoblastoid cells and development of impaired influx as a mechanism of resistance to lipophilic antifolates. Cancer Res 48:6986–6991, 1988

    Google Scholar 

  19. Goldman ID: The characteristics of the membrane transport of amethopterin and the naturally occurring folates. Ann NY Acad Sci 186:400–422, 1971

    Google Scholar 

  20. Plagemann PGW, Wohlhueter RM: Permeation of nucleosides, nucleic acid bases, and nucleotides in animal cells. Curr Topics Membranes Transport 14:225–330, 1980

    Google Scholar 

  21. Kelley EE, Modest EJ, Burns CP: Unidirectional membrane uptake of the ether lipid antineoplastic agent edelfosine by L1210 cells. Biochem Pharmacol 45:2435–2439, 1993

    Google Scholar 

  22. Vasanhakumar G, Ahmed NK: Comparative uptake, retention and cytotoxicity of daunorubicin by human myeloid cells. Biochem Pharmacol 35:1185–1190, 1986

    Google Scholar 

  23. Kamen BA, Eibl B, Cashmore A, Bertino J: Uptake and efficacy of trimetrexate (TMQ, 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline), a nonclassical antifolate in methotrexate-resistant leukemia cells in vitro. Biochem Pharmacol 33:1697–1699, 1984

    Google Scholar 

  24. Spinella MJ, Brigle KE, Sierra EE, Goldman ID: Distinguishing between folate receptor-α-mediated transport and reduced folate carrier-mediated transport in L1210 leukemia cells. J Biol Chem 270:7842–7849, 1995

    Google Scholar 

  25. Kamen BA, Johnson CA, Wang M-T, Anderson RGW: Regulation of the cytoplasmic accumulation of 5-methyltetrahydrofolate in MA104 cells is independent of folate receptor regulation. J Clin Invest 84:1379–1386, 1989

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Warner-Lambert Company, Parke-Davis Pharmaceutical Research, 48105, Ann Arbor, Michigan, USA

    Kenneth E. Hook, Sally A. Przybranowski & W. R. Leopold

Authors
  1. Kenneth E. Hook
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sally A. Przybranowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W. R. Leopold
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hook, K.E., Przybranowski, S.A. & Leopold, W.R. Cellular transport of CI-980. Invest New Drugs 14, 341–347 (1996). https://doi.org/10.1007/BF00180809

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00180809

Key words

Search

Navigation